Ionis Pharmaceuticals reported highly positive outcomes from two pivotal Phase III trials assessing olezarsen, an antisense oligonucleotide targeting apolipoprotein-CIII for severe hypertriglyceridemia. The CORE and CORE2 trials demonstrated up to 72% placebo-adjusted mean triglyceride reductions and an 85% decrease in acute pancreatitis events, with favorable safety profiles. CEO Brett P. Monia emphasized olezarsen’s potential to meet a substantial unmet clinical need and possibly become a blockbuster drug upon supplemental FDA approval anticipated in 2026. This breakthrough may reshape treatment paradigms for patients at risk of pancreatitis due to high triglycerides.